Case Studies: In-Process Testing Failures That Led to Batch Rejection

Case Studies of In-Process Testing Failures and Resulting Batch Rejections in Pharmaceutical Manufacturing

In process controls in pharmaceutical manufacturing are essential tools designed to monitor and ensure product quality during various stages of production. These controls help detect deviations and non-conformities early, allowing for corrective actions before final product release. However, when in-process testing fails, the consequences can be significant, often culminating in costly batch rejections. This article presents detailed step-by-step tutorial-style case studies that elucidate how failed IPC (in-process controls), insufficient investigations, and inappropriate rework practices have led to batch rejection within regulatory frameworks applicable in the US, UK, and EU.

Understanding the Role of In Process Controls in Pharmaceutical Manufacturing

In-process controls (IPC) are predefined, scientifically justified testing and monitoring activities performed during pharmaceutical manufacturing to verify that the process operates within established parameters. IPCs serve as checkpoints to prevent batch failures and ensure compliance with cGMP requirements such as those outlined in FDA 21 CFR Part 211 and EU GMP Volume 4 guidelines. Their purpose is to detect deviations at an early stage, allow timely intervention, and thereby avoid production of out-of-specification (OOS) or non-compliant batches.

The most common IPC points are sampling and testing of raw materials, intermediate products, in-process blend uniformity, moisture content, pH, temperature profiles, and critical parameters specific to the process such as granule size or dissolution rate. These data guide manufacturing personnel about process stability and product quality to ensure that critical quality attributes (CQAs) remain within justified limits.

Failure of IPC results in identification of discrepancies that require formal investigation as per ICH Q9 quality risk management and WHO GMP principles. An effective investigation evaluates root causes and determines whether rework is feasible or if the batch must be rejected entirely to ensure patient safety and regulatory compliance.

Case Study 1: Failed Granule Moisture Content Testing Leading to Batch Rejection

Background: During the wet granulation phase of a tablet manufacturing campaign in an EU-regulated facility, in-process moisture content testing is conducted to ensure proper granule drying. The set limit is defined at 2.5% ± 0.3%, a critical parameter affecting tablet hardness and dissolution.

Incident: In-process sampling and loss on drying (LOD) testing of granules showed moisture content of 3.1%, exceeding the upper IPC limit. The batch was put on hold for further assessment. The IPC failure was documented as an OOS result in the batch manufacturing record.

Also Read: Statistical Tools for Evaluating Uniformity of Dosage Units

Step 1: Immediate Actions and Documentation

Operators halted further processing upon receiving the failed IPC result.
An immediate deviation report was generated, and the quality unit was notified per the site SOP for OOS/IPC failures.
All affected documentation, including sampling logs, instrument calibration records, and environmental conditions, were collated.

Step 2: Investigation

The cross-functional investigation team (manufacturing, quality, and process engineering) convened.
Review of drying equipment settings, validation protocols, and recent maintenance showed that the spray dryer had an incorrectly calibrated moisture sensor, which led to ineffective drying cycles.
Environmental monitoring records indicated elevated humidity levels in the drying room compared to historical averages.

Step 3: Root Cause Analysis

Root cause was determined to be a combination of improper equipment calibration and a transient environmental deviation.
Operator training records were reviewed and found current; process controls for humidity were inadequate.

Step 4: Corrective and Preventive Actions (CAPA)

Immediate recalibration and qualification of the moisture sensor on the spray dryer.
Installation of additional humidity controls and monitoring in the drying area.
Updating SOPs to include environmental parameter checks prior to critical drying steps.
Retraining of operators on the importance of environmental monitoring during drying.

Step 5: Rework Assessment and Final Disposition

Re-testing of moisture content post re-drying exceeded time limits validated for the granule stability.
Risk assessment determined that rework would compromise the CQAs of the batch and may lead to non-uniformity.
The quality unit approved batch rejection based on insufficient data to assure product quality preservation.

Outcome: The batch was rejected and destroyed. The case highlighted the criticality of accurate IPC testing and environmental controls within pharmaceutical manufacturing.

Case Study 2: Failed Blend Uniformity Test and Gap in Investigation Resulting in Extended Batch Hold

Background: A large-scale powder blending step was monitored through in-process blend uniformity testing, an IPC designed to ensure content uniformity before compression. The acceptance criteria followed the statistical limits described in EU GMP Volume 4.

Incident: The first blend uniformity sample showed significant API assay variability with %RSD exceeding 7%, above the defined IPC limit of 5%. The batch was not processed further until investigation and corrective actions were completed.

Step 1: Initial Containment and Sampling

Sampling for blend uniformity testing was suspended immediately.
The blending operation was stopped, and the blend container was isolated.

Step 2: Investigation Planning

A formal investigation was launched but initially focused on sampling and analytical method validity without thoroughly assessing manufacturing process parameters.
Laboratory controls verified correct sample handling, and no analytical instrument deviations were found.

Step 3: Expanded Root Cause Analysis

Further inquiry revealed that blending time had been shortened due to schedule pressures, shortening validated mixing time from 15 minutes to 8 minutes on this batch.
The blender load pattern was inconsistent with the validated loading sequence, potentially contributing to non-uniform distribution.
Investigation found incomplete training documentation on altered blending parameters and no documented risk assessment for deviation.

Also Read: Microbiology QC Laboratory Controls for Non-Sterile Products

Step 4: Corrective Measures and Rework Decision

A re-blending step was proposed and evaluated for feasibility and potential impact on product quality by the quality unit and process validation teams.
Re-blending studies on small-scale batches demonstrated that additional blending restored uniformity within IPC limits.
CAPA included personnel training updates, process control enhancements, and revision of SOPs emphasizing minimum blending times and load patterns.

Step 5: Regulatory and Documentation Considerations

Due to the initially incomplete investigation, the batch experienced extended hold times, triggering a formal notification to regulatory authorities consistent with PIC/S GMP guidelines.
All rework activities, along with rationale and experimental data, were documented and subjected to quality unit approval before batch release.

Outcome: Mechanical rework via re-blending restored blend uniformity. The batch was ultimately released after successful IPC verification, but the episode underscored the consequences of incomplete investigations and the importance of strict adherence to validated process parameters.

Case Study 3: IPC Failure in pH Control During Aseptic Processing Leading to Batch Rejection

Background: In aseptic fill-finish of a sterile injectable product manufactured under stringent cleanroom conditions, in-process pH testing serves as a critical control point to detect formulation drift or contamination risks.

Incident: During filling, IPC pH results for multiple consecutive samples fell outside established acceptance criteria (pH 6.8–7.2), with values recorded at 7.5–7.7. The abnormal results triggered a production stop and thorough investigation.

Step 1: Immediate Containment Actions

Filling was suspended immediately, and all partially filled containers were quarantined.
Environmental and process parameters (temperature, humidity, cleanroom particle counts) were reviewed.

Step 2: Investigation

Cross-functional team assessed multiple potential root causes including raw material variability, pH meter calibration, formulation preparation process, and possible contamination events.
Review of incoming raw material data revealed one batch of buffer salt used during preparation had an elevated pH specification at the upper limit.
Calibration certificates for analytical instruments were verified; however, pH meter probes showed signs of wear.
Environmental monitoring upheld cleanroom classification and no microbial contamination was detected.

Step 3: Root Cause Determination

Root cause was multifactorial: marginal raw material pH combined with inaccurate pH measurement due to aging probes.
These factors caused deviations in formulation pH, impacting aseptic filling parameters.

Step 4: CAPA Implementation

Immediate replacement and enhanced maintenance schedule for pH probes.
Supplier qualification tightened to ensure raw material pH tighter within target ranges.
Process parameters adjusted to add inline pH measurement and control in real-time.
Training updated emphasizing importance of equipment calibration in IPC reliability.

Also Read: In-Process Controls in Pharmaceutical Manufacturing: What Regulators Expect

Step 5: Batch Disposition

Due to potential risk to sterility and product stability, reworking the affected batch was not possible.
Quality unit released the batch for destruction in accordance with site procedures and regulatory requirements.

Outcome: The case highlighted the critical nature of equipment calibration, raw material controls, and robust IPC strategies in sterile manufacturing environments.

Best Practices for Managing In-Process Controls and Failures

The above case studies demonstrate the importance of rigorous adherence to IPC strategies, thorough investigations, documented rework justifications, and unambiguous decision-making regarding batch disposition. Pharmaceutical sites should adopt the following best practices to minimize risk associated with failed IPC:

Scientific Justification and Validation of IPC Parameters: All IPC limits must be based on validated, risk-assessed critical quality attributes supported by process validation and product characterization data. This ensures reproducible and meaningful monitoring.
Real-Time Monitoring and Prompt Reporting: Operators and QA personnel must be trained to promptly detect and report IPC failures using structured deviation and OOS procedures compliant with ICH Q10 quality systems.
Comprehensive Root Cause Investigation: Investigations must be interdisciplinary, incorporating manufacturing, quality, engineering, and analytical expertise. Investigations should not be limited to symptoms but seek to identify systemic failures.
Robust Documentation: All aspects of IPC testing, failures, investigations, corrective/preventive actions, and final batch disposition must be meticulously documented in batch records, investigation reports, and quality management systems.
Validated Rework Procedures before Implementation: If rework is considered, its impact on CQAs, process parameters, and stability must be scientifically and regulatorily justified and validated prior to use.
Preventive Controls and Continuous Improvement: Findings from failed IPC cases should feed into CAPA systems driving improvements in operator training, equipment maintenance, supplier controls, and process robustness.

Implementing these best practices aligns with regulatory expectations from agencies such as FDA, EMA, MHRA, and WHO and supports a culture of quality consistent with ICH Q9 risk management and Q10 pharmaceutical quality system guidelines.

Conclusion

In-process controls in pharmaceutical manufacturing are paramount to ensuring batch quality and compliance with Good Manufacturing Practices. The case studies reviewed illustrate how failed IPC, if poorly managed or investigated, lead to significant operational and regulatory consequences including batch rejection. However, they also demonstrate that robust investigation, documentation, and scientifically justified corrective and preventive measures can support process improvement and eventual batch release where feasible.

Manufacturers operating in the US, UK, and EU should continuously refine their in-process monitoring strategies and ensure education and quality system rigor to minimize failed IPC events. Maintaining transparent and thorough investigation practices, coupled with validated rework protocols and comprehensive risk assessments, safeguards patient safety and supports compliance with contemporary GMP standards.